CC

Cryo-Cell International IncNYSE-MKT CCEL Stock Report

Last reporting period 31 May, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

0.05

Micro

Exchange

XASE - Nyse MKT LLC

CCEL Stock Analysis

CC

Uncovered

Cryo-Cell International Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-17/100

Low score

Market cap $B

0.05

Dividend yield

12.21 %

Shares outstanding

8.443 B

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 80 full-time employees. The firm operates through three segments: The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use; the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells, and the cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals. The Company, in combination with its global affiliates, stores approximately 500,000 cord blood and cord tissue specimens around the world for the benefit of newborn babies and possibly other members of their families. Its processing and storage of specimens is handled from its facility in Oldsmar, Florida.

View Section: Eyestock Rating